Holbrook, New York, May 17, 2021 (GLOBE NEWSWIRE) -- Healixa, Inc. (OTC Pink: EMOR) (“Healixa”, or the “Company”), a healthcare technology company delivering seamless and instant virtual care from your smartphone by combining healthtech and fintech to offer digital pharmacy, virtual patient monitoring and digital pharmacy subscription services, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.
The initiation report provides an overview of recent events, new initiatives, as well as a recent acquisition in the space which favorably impacts the company valuation relative to its peer group. The sponsored research also carries a rating and a price target and can be accessed at https://emerginggrowth.com/marble-arch-research-report-healixa-inc-otc-pink-emor/
In the update report released today, Marble Arch Research notes that, “Using a comps-based valuation approach, we believe EMOR should be trading at $2.8-$3.3 per share vs the prevailing $1.20. Acknowledging that Healixa is in the very early stages of commercializing its virtual care ecosystem, we place a Speculative Buy recommendation on the stock, but put it on watch to a possible upgrade to a firm BUY as we monitor the company’s early operational progress, moves towards a main board uplisting...”
About Healixa Inc.
Healixa Inc., formerly known as Emerald Organic Products Inc., is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith PCG Advisory, Inc. 1-646-823-8656 ksmith@pcgadvisory.com